BioSpace News Archive

Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery.

Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health.

The demand within the global immunoprotein diagnostic market is slated to reach unprecedented heights in the years to follow.

The global CTC diagnostics market is projected to exhibit a steady growth owing to the increasing demand for diagnostic devices for cancer research and diagnosis.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the appointment of Devin W. Smith as Senior Vice President and General Counsel.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced updates on its ALX148 Phase 2 studies in patients with advanced head and neck squamous cell carcinoma.

Anavex Life Sciences Corp. reported that ANAVEX®2-73 and ANAVEX®3-71 are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled “The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer’s”.

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the Company will participate in the JMP Securities Life Sciences Conference.

Terns Pharmaceuticals, Inc. reported positive top-line results from the Phase 2a LIFT clinical trial of TERN-101, a liver-distributed farnesoid X receptor agonist for the treatment of patients with NASH.

Nevro Corp. today announced it will host an analyst & investor briefing from the American Diabetes Association 81st Scientific Sessions on Friday, June 25, 2021, beginning at 3:30 pm PT / 6:30 pm ET.